JPH08511006A - 安定な銅（▲ｉ▼）錯体及びそれに関する方法 - Google Patents

安定な銅（▲ｉ▼）錯体及びそれに関する方法

Info

Publication number
JPH08511006A
JPH08511006A JP7501073A JP50107395A JPH08511006A JP H08511006 A JPH08511006 A JP H08511006A JP 7501073 A JP7501073 A JP 7501073A JP 50107395 A JP50107395 A JP 50107395A JP H08511006 A JPH08511006 A JP H08511006A
Authority
JP
Japan
Prior art keywords
copper
complex
stable
stable copper
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP7501073A
Other languages
English (en)
Japanese (ja)
Inventor
ジェイ． パレンバーグ，アレクサンダー
ブランカ，アンドリュー
エム． マーシュナー，トーマス
エム． パット，レオナード
Original Assignee
プロサイト コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロサイト コーポレイション filed Critical プロサイト コーポレイション
Publication of JPH08511006A publication Critical patent/JPH08511006A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP7501073A 1993-06-02 1994-06-02 安定な銅（▲ｉ▼）錯体及びそれに関する方法 Pending JPH08511006A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7144093A 1993-06-02 1993-06-02
US08/071,440 1993-06-02
PCT/US1994/006247 WO1994027594A2 (fr) 1993-06-02 1994-06-02 Complexes stables de cuivre(i) et leur utilisation comme substances therapeutiques actives

Publications (1)

Publication Number Publication Date
JPH08511006A true JPH08511006A (ja) 1996-11-19

Family

ID=22101339

Family Applications (1)

Application Number Title Priority Date Filing Date
JP7501073A Pending JPH08511006A (ja) 1993-06-02 1994-06-02 安定な銅（▲ｉ▼）錯体及びそれに関する方法

Country Status (8)

Country Link
EP (1) EP0701439A1 (fr)
JP (1) JPH08511006A (fr)
AU (1) AU7051794A (fr)
CA (1) CA2163640A1 (fr)
OA (1) OA10198A (fr)
TW (1) TW239077B (fr)
WO (1) WO1994027594A2 (fr)
ZA (1) ZA943857B (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543885A (ja) * 2005-06-20 2008-12-04 ダイナミクリア ピーティーワイ リミテッド 皮膚病変治療用組成物
JP2014129346A (ja) * 2012-12-28 2014-07-10 Hung-Chien Chien 組み換えタンパク質、当該組み換えタンパク質を含む医薬組成物、及び前記組み換えタンパク質の製造方法
JP2014231525A (ja) * 2008-09-03 2014-12-11 株式会社Ｎｂｃメッシュテック 抗ウイルス剤
JP2021532066A (ja) * 2018-06-04 2021-11-25 ケミストリーアールエックス.Chemistryrx. 発毛を刺激するための局所的組成物

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562854B2 (en) 1994-12-14 2003-05-13 Axys Pharmaceuticals, Inc. Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders
AU6274896A (en) * 1995-06-06 1996-12-24 Procyte Corporation Stable copper(i) complexes as active therapeutic substances
US5637311A (en) * 1995-06-29 1997-06-10 Procyte Corporation Zinc(II) complexes and methods related thereto
US7045531B1 (en) 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
US6150379A (en) * 1997-11-26 2000-11-21 Axys Pharmaceuticals, Inc. Compounds and compositions as anticoagulants
US6638711B1 (en) 1999-04-29 2003-10-28 The General Hospital Corporation Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
CA2568134A1 (fr) * 2004-05-24 2005-12-08 New York University Methode de traitement ou de prevention d'effets pathologiques d'augmentations aigues de l'hyperglycemie et/ou d'augmentations aigues de flux d'acides gras libres
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
US11331288B2 (en) 2017-09-14 2022-05-17 The Board Of Trustees Of The Leland Stanford Junior University Conditioning irradiated tissue for increasing vascularity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760051A (en) * 1985-01-24 1988-07-26 Pickart Loren R Use of GHL-Cu as a wound-healing and anti-inflammatory agent
JPS6259213A (ja) * 1985-09-10 1987-03-14 Eisai Co Ltd ス−パ−オキサイド除去剤

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543885A (ja) * 2005-06-20 2008-12-04 ダイナミクリア ピーティーワイ リミテッド 皮膚病変治療用組成物
JP2014231525A (ja) * 2008-09-03 2014-12-11 株式会社Ｎｂｃメッシュテック 抗ウイルス剤
JP2014129346A (ja) * 2012-12-28 2014-07-10 Hung-Chien Chien 組み換えタンパク質、当該組み換えタンパク質を含む医薬組成物、及び前記組み換えタンパク質の製造方法
JP2021532066A (ja) * 2018-06-04 2021-11-25 ケミストリーアールエックス.Chemistryrx. 発毛を刺激するための局所的組成物

Also Published As

Publication number Publication date
EP0701439A1 (fr) 1996-03-20
ZA943857B (en) 1995-02-01
WO1994027594A3 (fr) 1995-04-27
TW239077B (fr) 1995-01-21
AU7051794A (en) 1994-12-20
WO1994027594A2 (fr) 1994-12-08
OA10198A (en) 1996-12-18
CA2163640A1 (fr) 1994-12-08

Similar Documents

Publication Publication Date Title
Biller et al. Squalene synthase inhibitors
Meier et al. cyclo Sal-Pronucleotides of 2 ‘, 3 ‘-Dideoxyadenosine and 2 ‘, 3 ‘-Dideoxy-2 ‘, 3 ‘-didehydroadenosine: Synthesis and Antiviral Evaluation of a Highly Efficient Nucleotide Delivery System
Morales-Ruiz et al. Transduction of the liver with activated Akt normalizes portal pressure in cirrhotic rats
JPH08511006A (ja) 安定な銅（▲ｉ▼）錯体及びそれに関する方法
CA2222224A1 (fr) Analogues de nucleotides utiles pour le traitement topique de maladies proliferatives de la peau
JP2009242438A (ja) ノルジヒドログアヤレティク酸誘導体を使用して腫瘍を処置するための方法
JP2003511477A (ja) 腫瘍の処置における使用のためのノルジヒドログアイアレチン酸誘導体
Peterson et al. Cationic neutrophil proteins increase transendothelial albumin movement
EP1231916A2 (fr) Utilisation de derives d'indirubine pour la fabrication de medicaments
EP0752872B1 (fr) Nadh oxydase utilisee comme cible dans des procedes de diagnostic et therapeutiques
WO1996039144A1 (fr) Complexes cuivreux stables utilises comme substances a activite therapeutique
Monti et al. Anti-hypertensive property of a nickel-piperazine/NO donor in spontaneously hypertensive rats
Poulsen et al. Studies on esterases in the chicken central nervous system
Saraswathi et al. Inhibition of glycolysis and respiration of sarcoma-180 cells by echitamine chloride
WO1997001559A1 (fr) Complexes de zinc(ii) et procedes relatifs a leur utilisation
US20020128248A1 (en) SODm therapy for prevention and/or treatment of inflammatory disease
Van Gelder et al. Inhibition of intestinal metabolism of the antiviral ester prodrug bis (POC)-PMPA by nature-identical fruit extracts as a strategy to enhance its oral absorption: an in vitro study
Bertrand et al. Role of tumour necrosis factor-α and inducible nitric oxide synthase in the prevention of nitro-flurbiprofen small intestine toxicity
Tedde et al. Effects of 2′-deoxycoformycin infusion on mouse adenosine deaminase
EP0316117A1 (fr) Composés antiviraux, compositions contenant de tels composés et méthodes de traitement
Parang et al. Synthesis, in vitro anti-human immunodeficiency virus structure—activity relationships and biological stability of 5′-O-myristoyl analogue derivatives of 3′-azido-2′, 3′-dideoxythymidine (AZT) as potential prodrugs
Satoh et al. Inhibition of Na+, K+-ATPase by the extract of Stephania cephararantha Hayata and bisbenzylisoquinoline alkaloid cycleanine, a major constituent
Chavan et al. Inactivation of human immunodeficiency virus type 1 reverse transcriptase by oltipraz: evidence for the formation of a stable adduct
US3974187A (en) Synthetic analogs having the activity of naturally occurring forms of coenzyme Q
US5405875A (en) Method of inhibiting neoplasia and tumor promotion